Welcome to our dedicated page for Ardelyx SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ardelyx, Inc. (Nasdaq: ARDX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a biopharmaceutical issuer with commercial products IBSRELA and XPHOZAH and an active development pipeline, Ardelyx uses SEC reports to describe its financial condition, risk factors, governance and material corporate events.
Current reports on Form 8-K referenced in recent disclosures cover topics such as quarterly financial results, amendments to loan and security agreements, changes to equity incentive plans and bylaws, and transitions in senior management roles. For example, Ardelyx has filed 8-Ks describing appointments and resignations of executive officers, the approval of amendments to its 2014 Equity Incentive Award Plan at the annual meeting of stockholders, and changes to its loan facilities, including new term loans and updated maturity dates.
On this page, users can also locate periodic reports such as Forms 10-K and 10-Q, which contain detailed financial statements, management’s discussion and analysis, descriptions of the company’s products IBSRELA and XPHOZAH, discussions of its NHE3 inhibitor pipeline and summaries of key risks related to drug development and commercialization. These filings provide context for revenue from tenapanor-based products, licensing arrangements with partners such as Kyowa Kirin, Fosun Pharma and Knight Therapeutics, and capital structure information.
Stock Titan enhances access to Ardelyx filings with AI-powered summaries that highlight important sections in lengthy documents, such as annual reports on Form 10-K and quarterly reports on Form 10-Q. Users can also review filings related to executive compensation, equity plans and governance changes, as disclosed in proxy materials and associated 8-Ks. Real-time updates from the EDGAR system help ensure that new Ardelyx filings, including future 8-Ks reporting material events, are reflected promptly for investors and researchers.
Eric Duane Foster, Chief Commercial Officer of Ardelyx, Inc. (ARDX), reported a routine stock transaction dated 08/21/2025. Pursuant to an automatic sell-to-cover tied to the vesting of restricted stock units, 15,308 shares of Common Stock were sold at an average price of $5.9317 per share to satisfy applicable tax withholding. After the sale, Mr. Foster beneficially owned 301,498 shares. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Foster on 08/25/2025. No derivatives or other transactions are reported.
Ardelyx, Inc. is reported to have a significant institutional stake held by Janus Henderson Group plc. The filing shows Janus Henderson beneficially owns 15,057,940 shares, representing 6.3% of the outstanding common stock, with shared voting and shared dispositive power over 15,057,940 shares. A related subsidiary, JHIUS, is disclosed as potentially beneficial owner of 14,928,999 shares (6.2%) and, together with JHIUKL and JHIAIFML, is identified as an indirect subsidiary that serves as a registered investment adviser to Managed Portfolios. The filer certifies these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Ardelyx (ARDX) Q2-25 10-Q highlights
Total revenue rose 33% YoY to $97.7 m, driven by 84% growth in IBSRELA sales to $65.0 m. XPHOZAH sales fell 33% to $25.0 m after Medicare moved the drug into the ESRD PPS bundle on 1 Jan 25. Six-month revenue reached $171.8 m (+44%).
Gross margin remained high; cost of goods sold was $12.4 m (12.7% of revenue). Operating expenses climbed 29% to $99.7 m as SG&A spending supporting commercial expansion hit $84.0 m; R&D was $15.7 m. Net loss widened to $19.1 m (-$0.08/sh) versus -$16.5 m (-$0.07/sh) a year earlier; six-month loss totalled $60.2 m.
Balance sheet: cash, equivalents and short-term investments stand at $238.5 m. On 30 Jun 25 Ardelyx drew a new $50 m Term E loan, lifting total debt to $201.4 m; another $100 m is available through 2026. Interest-only payments run to Jul-28, but the blended rate on existing tranches is SOFR + 4–8% plus fees.
Other items: a $5 m milestone from Fosun (China NDA approval) booked in Q1. Non-cash royalty revenue from Kyowa Kirin (Japan) was $1.4 m. The $75 m AstraZeneca termination royalty is now fully amortized. Litigation over CMS bundling of XPHOZAH continues; oral arguments are scheduled for Sep-25.
Liquidity runway is solid, but profitability depends on sustaining IBSRELA momentum and offsetting XPHOZAH reimbursement headwinds.
Ardelyx, Inc. (ARDX) has amended its February 2022 Loan & Security Agreement for the fifth time, securing an immediate $50 million senior secured term loan ("Term E") and gaining access to an additional $100 million of committed capital in two optional $50 million tranches ("Term F" and "Term G").
Key economics include: (1) Term E pricing at 4.00% plus 0.022% plus 1-month SOFR, with a SOFR floor of 4.70%; (2) optional Term F/G pricing at SOFR + 4.95%, floored at 3.50%; (3) interest-only payments until maturity—July 1, 2028 for Term E and July 1, 2030 for Term F/G. The company paid a $250k draw fee for Term E and a $1.0 million facility fee for the incremental loans.
The facility remains collateralized and carries back-end fees of 4.95% (Term E) and 3.45% (Term F/G) of principal, payable upon maturity, acceleration, or prepayment. No changes were disclosed to covenants or security packages.
Investment view: The amendment immediately bolsters liquidity and provides flexible growth or runway capital through 2026, but materially increases secured debt capacity and locks in high floating-rate interest costs. Investors should weigh the near-term cash benefit against potential future leverage and interest-expense drag.
Millennium Management LLC, along with affiliated entities, has reported acquiring a significant stake in Ardelyx. According to the Schedule 13G filing dated June 28, 2025, the reporting persons collectively own 12,099,947 shares, representing a 5.1% ownership in the company.
The reporting persons include:
- Millennium Management LLC (Delaware)
- Millennium Group Management LLC (Delaware)
- Israel A. Englander (United States)
All three parties share voting and dispositive power over the reported shares, with no sole voting or dispositive power. The securities were not acquired for the purpose of changing or influencing control of Ardelyx. The shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers controlled by Millennium Group Management LLC and Mr. Englander.
Ardelyx, Inc. (ARDX) – Form 4 insider transaction filed 06/23/2025
Board member Richard J. Rodgers reported routine, compensation-related equity grants dated 06/18/2025 under Ardelyx’s Non-Employee Director Compensation Program:
- 21,468 common shares issued in lieu of cash fees, increasing his direct holdings to 371,992 shares.
- 41,551 restricted stock units (RSUs); each RSU converts 1-for-1 to common stock as it vests, bringing total directly held shares to 413,543 on a fully delivered basis.
- 54,059 stock options with a $3.61 exercise price, 10-year term (expiring 06/18/2035). Vesting is 1/12 monthly with full acceleration at the next annual meeting if service continues.
No sales were reported and all awards were granted at $0 cost to the director. Transactions reflect standard annual director compensation and represent a small, immaterial dilution to existing shareholders.
On 18 June 2025, Ardelyx, Inc. (ARDX) filed a Form 4 disclosing that director Merdad Parsey received 15,235 shares of the company’s common stock. The shares were issued at a price of $0 under the company’s Non-Employee Director Compensation Program, reflecting the director’s election to take equity instead of cash fees. Following the transaction, Parsey’s direct beneficial ownership stands at 57,291 shares. No sales, dispositions, or derivative security activities were reported, and the filing contains no additional financial metrics.